About pliant therapeutics inc - PLRX
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. It offers a product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
PLRX At a Glance
Pliant Therapeutics, Inc.
331 Oyster Point Boulevard
South San Francisco, California 94080
| Phone | 1-650-481-6770 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -210,304,000.00 | |
| Sector | Health Technology | Employees | 171 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PLRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.636 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.218 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.12 |
PLRX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,229,847.953 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PLRX Liquidity
| Current Ratio | 10.906 |
| Quick Ratio | 10.906 |
| Cash Ratio | 10.709 |
PLRX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -46.266 |
| Return on Equity | -54.087 |
| Return on Total Capital | -57.733 |
| Return on Invested Capital | -49.637 |
PLRX Capital Structure
| Total Debt to Total Equity | 19.795 |
| Total Debt to Total Capital | 16.524 |
| Total Debt to Total Assets | 15.164 |
| Long-Term Debt to Equity | 19.616 |
| Long-Term Debt to Total Capital | 16.375 |